This website is for UK Healthcare Professionals only

Video library

Haematology experts provide their opinions on key topics in the treatment of AML

VIALE-A: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Dr. Richard Dillon provides an overview of the VIALE-A trial of azacitidine and venetoclax in previously untreated acute myeloid leukemia patients who were ineligible for intensive chemotherapy

Management strategies and real-world experience with venetoclax in first-line AML

Watch Dr. Richard Dillion discuss his  experience using venetoclax in clinical practice and how he manages venetoclax treatment in first-line AML

Expert opinion: Using venetoclax in first-line chemotherapy-ineligible AML

Watch Professor Nigel Russel discuss venetoclax treatment in first-line AML patients ineligible for intensive chemotherapy

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCAML-220118. Date of preparation: April 2022.